ACIU 財務： AC Immune SA AI 分析

Q: AC Immune SA 的關鍵財務報表是什麼？

根據最新的財務報表（Form-10K），AC Immune SA 的總資產為 $230，淨損失為 $-50

Q: ACIU 的關鍵財務比率是什麼？

AC Immune SA 的流動比率為 1.94，淨利潤率為 -185.18，每股銷售為 $0.27。

Q: AC Immune SA 的收入按細分市場或地理位置如何劃分？

AC Immune SA 最大收入來源為 Therapeutic and Diagnostic Products，在最近的收益報告中收入為 31,009,430。就地區而言，Switzerland 是 AC Immune SA 的主要市場，收入為 31,009,430。

Q: AC Immune SA 是否盈利？

無，根據最新的財務報表，AC Immune SA 的淨損失為 $-50

Q: AC Immune SA 有負債嗎？

是的，AC Immune SA 的負債為 118

Q: AC Immune SA 的流通股有多少？

AC Immune SA 的總流通股為 100.41

首頁

股票

ACIU

ACIU 財務

AC Immune SA

$3.32

-5.41%

$-0.18

截至今日：Jan 20, 15:36:50 GMT-5

概觀預測收益股利財務狀況

關鍵數據

前收市價

$3.51

開盤價

$3.53

當日範圍

$3.32 - $3.59

52週區間

$1.43 - $4

交易量

361.5K

平均成交量

713.5K

每股盈餘 (TTM)

-0.72

股息收益率

市值

$333.3M

什麼是 ACIU？

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 133 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

功能特性

交易策略

資源

市場

收入

資產負債表

現金流量

年度

每季

ACIU 收入

財務數據以百萬美元計。會計年度為二月至一月。

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
營收	4	27	14	3	0	15
營收年增率 (YoY)	-90%	93%	367%	--	-100%	-86%
營收成本	--	--	--	--	--	--
毛利	--	--	--	--	--	--
銷售、一般及管理費用	11	11	10	9	10	11
研發	61	62	54	60	62	59
營業費用	77	79	68	74	79	76
其他非營業收入 (費用)	--	--	--	--	0	0
稅前淨利	-71	-50	-54	-70	-73	-61
所得稅費用	0	0	0	0	0	0
淨利	-71	-50	-54	-70	-73	-61
淨利成長	82%	-7%	-23%	-4%	20%	-236%
稀釋後流通股數	100.89	99.69	84.69	83.6	75	71.9
股數年變動 (YoY)	0%	18%	1%	11%	4%	1%
每股盈餘 (稀釋)	-0.71	-0.51	-0.64	-0.85	-0.97	-0.86
每股盈餘成長率	75%	-20%	-25%	-12%	13%	-234%
自由現金流	-47	65	-61	-74	-68	-61
每股自由現金流	--	--	--	--	--	--
毛利率	--	--	--	--	--	--
營業利益率	-1,825%	-192.59%	-378.57%	-2,333.33%	0%	-406.66%
淨利率	-1,775%	-185.18%	-385.71%	-2,333.33%	0%	-406.66%
自由現金流利潤率	-1,175%	240.74%	-435.71%	-2,466.66%	0%	-406.66%
EBITDA	-71	-50	-51	-68	-77	-60
EBITDA 利潤率	-1,775%	-185.18%	-364.28%	-2,266.66%	0%	-400%
EBITDA 中的折舊與攤銷	2	2	2	2	2	1
EBIT	-73	-52	-53	-70	-79	-61
EBIT 利潤率	-1,825%	-192.59%	-378.57%	-2,333.33%	0%	-406.66%
有效稅率	0%	0%	0%	0%	0%	0%

Follow-Up Questions

AC Immune SA 的關鍵財務報表是什麼？



ACIU 的關鍵財務比率是什麼？



AC Immune SA 的收入按細分市場或地理位置如何劃分？



AC Immune SA 是否盈利？



AC Immune SA 有負債嗎？



AC Immune SA 的流通股有多少？



AC Immune SA（ACIU）價格

ACIU 股價走勢圖